MediBeacon’s use of proprietary fluorescent tracer agents coupled with transdermal detection technology focuses on providing vital and actionable measurement of organ function.
The Company’s Transdermal GFR System (TGFR) is engineered for noninvasive detection of the change in levels of a fluorescent GFR tracer agent over time via a sensor placed on the patient’s skin. The TGFR Sensor measures the intensity of Lumitrace® fluorescence 2.5 time per second. The rate of change in the emitted fluorescence from Lumitrace is automatically calculated and displayed on the monitor yielding a transdermal GFR (tGFR).